Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Lite Strategy, Inc. LITS

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-71.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -15.9
25.0M50.0M-20.0M-40.0M
2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating 22.3% · Net 27.2%
-500%-1000%-1500%
200720162025
ROE
FY2025 · ROE -243.0%
20%40%60%-100%-200%
200720162025
Three returns, three denominators.

Each USD of equity lost 243 cents this year.

Cash & shareholders

USD 267,000.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -20.8
15M30M-20M-40M
200720162025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 0.3
5M10M
2022202320242025

USD 267,000.00 in buybacks went back to shareholders in a year without profit.

Total assetsUSD 42.7M
EquityUSD 41.6M
CashUSD 5.7M
Current ratio5.74×

Equity funds 97% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LITS, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B◌0.00.10.00.00.00.00.00.00.0◌◌◌◌◌◌◌◌◌
Operating income $B−0.1−0.00.0−0.0−0.1−0.1−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B−0.1−0.00.0−0.0−0.1−0.1−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0◌◌◌
Net income $B−0.1−0.00.0−0.0−0.1−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌−0.0−0.1−0.1−0.0−0.00.0−0.0◌0.0−0.0−0.0−0.0−0.0◌−0.0◌◌◌
EPS, diluted $−2.06−2.392.67−4.78−9.99−0.60−0.52−0.75−0.970.07−0.61−1.16−1.35−1.10−3.35−0.89◌◌◌
Dividend / sh $◌◌1.75◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %—−065−0———————————————
ROE %−243.0−63.862.5−83.1−106.0−64.8−75.5−34.2−79.15.8−41.1−62.3−67.8−56.7−235.4−147.8−69.9−70.4−75.1
Shares out B0.030.010.010.010.130.110.110.070.070.040.030.030.020.020.020.01◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 67 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Nine checks were skipped: revenue is not tagged before 2016. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image